Rigel reports Q4 2022 net income $1.4M on record TAVALISSE sales of $21.9M; full year revenue $120.2M

RIGEL PHARMACEUTICALS INC

Q4 total revenue $51.3M ($21.9M TAVALISSE + $0.9M REZLIDHIA); net income $1.4M ($0.01/share) vs net loss $22.6M in Q4'21.
Full year 2022 net loss $58.6M ($0.34/share) on revenue $120.2M, compared to net loss $17.9M in 2021.
TAVALISSE 2022 net product sales $75.8M, up 20% YoY; Q4 bottles shipped to patients/clinics a record.
REZLIDHIA launched in Dec '22, $0.9M in Q4 sales; added to NCCN Guidelines for AML in Jan '23.
Cash and investments $58.2M at Dec 31, 2022, down from $125.0M at Dec 31, 2021.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

RIGEL PHARMACEUTICALS INC reported fourth quarter and year ended December 31, 2022 results: revenue $51.3 million, net income $1.4 million, or $0.01 per basic and diluted share, EPS $0.01 per basic and diluted share.

Period: fourth quarter and year ended December 31, 2022
Revenue: $51.3 million
Net income: $1.4 million, or $0.01 per basic and diluted share
EPS: $0.01 per basic and diluted share
Result: reported results

Exact text from the filing

EXHIBIT 99.1 Exhibit 99.1 Rigel Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update ● Fourth quarter 2022 Total Revenue of $51.3 million which includes TAVALISSE ® net product sales of $21.9 million and REZLIDHIA TM net product sales of $0.9 million ● REZLIDHIA U.S. commercial launch continues to progress and

View on SEC.gov

59 earnings releases filed in the last 30 days. Browse all earnings releases →

RIGEL PHARMACEUTICALS INC filing history →

Source: SEC EDGAR

accession 0001104659-23-029558

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.